Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ulonivirine - Merck Sharp & Dohme

Next Previous
Drug Profile

Ulonivirine - Merck Sharp & Dohme

Alternative Names: MK-8507

Latest Information Update: 31 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antiretrovirals; Benzonitrile; Chlorinated hydrocarbons; Ethers; Fluorinated hydrocarbons; Pyridazines; Pyrimidines
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 26 Dec 2025 Merck Sharp & Dohme plans a phase I trial for HIV 1 infections in January 2026 (PO) (NCT07305831)
  • 05 Dec 2025 Merck Sharp & Dohme plans a phase II/III trial for HIV-1 infections (Treatment-Naïve, Combination therapy) in January 2026 (PO) (NCT07266831)
  • 30 Jan 2025 Merck Sharp & Dohme Corp completes a phase II trial for HIV-1 Infection (Combination therapy) in France, Switzerland and USA (NCT04564547) (EudraCT2020-003071-18)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top